PMID- 33987273
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231123
IS  - 2305-5839 (Print)
IS  - 2305-5847 (Electronic)
IS  - 2305-5839 (Linking)
VI  - 9
IP  - 7
DP  - 2021 Apr
TI  - Cost-utility analysis of imrecoxib compared with celecoxib for patients with 
      osteoarthritis.
PG  - 575
LID - 10.21037/atm-21-290 [doi]
LID - 575
AB  - BACKGROUND: The objective of this study is to compare the long-term cost-utility 
      of imrecoxib and celecoxib for patients with osteoarthritis (OA) from the 
      perspective of the Chinese healthcare system. METHODS: An economic model was 
      built based on the model from the National Institute for Health and Care 
      Excellence (NICE). The simulation was carried out initially for 100 cycles of 3 
      months each, starting with 10,000 patients. A discount rate of 5% was applied 
      both for cost and utility. Quality-adjusted life years (QALYs) were adopted as 
      the utility indicator, and real-world data from the hospital information systems 
      of 170 hospitals was collected to indicate cost. The relative incidence rates of 
      adverse events (AEs) with imrecoxib and celecoxib were collected from randomized 
      controlled trials. Sensitivity analysis was performed to validate the robustness 
      of the model. RESULTS: In the base case analysis (6-month treatment duration, 55 
      years old and above), imrecoxib was the more cost-effective option compared to 
      celecoxib, with an incremental cost-effectiveness ratio (ICER) of $3,041.14. This 
      finding remained unchanged after varying the treatment duration and the age of 
      the patients. The main drivers of the results were the relative incidence of 
      myocardial infarction (MI), the cost of imrecoxib, and the utility of OA patients 
      without any AEs. Probability sensitivity analysis (PSA) showed that there was a 
      59.02% probability of imrecoxib as the more cost-effective option, with a 
      threshold of $30,000. CONCLUSIONS: Although there were uncertainties, imrecoxib 
      was the more cost-effective option compared to celecoxib, with a definite 
      possibility. Due to the limitations of the original model and this study, the 
      results of this study should be adopted with caution.
CI  - 2021 Annals of Translational Medicine. All rights reserved.
FAU - Sun, Xueshan
AU  - Sun X
AD  - Center for Health Policy Studies, School of Public Health, Zhejiang University 
      School of Medicine, Hangzhou, China.
FAU - Zhen, Xuemei
AU  - Zhen X
AD  - School of Health Care Management, Shandong University, Jinan, China.
AD  - NHC Key Laboratory of Health Economics and Policy Research (Shandong University), 
      Jinan, China.
FAU - Hu, Xiaoqian
AU  - Hu X
AD  - Center for Health Policy Studies, School of Public Health, Zhejiang University 
      School of Medicine, Hangzhou, China.
FAU - Li, Yuanyuan
AU  - Li Y
AD  - Center for Health Policy Studies, School of Public Health, Zhejiang University 
      School of Medicine, Hangzhou, China.
FAU - Gu, Shuyan
AU  - Gu S
AD  - Center for Health Policy and Management Studies, School of Government, Nanjing 
      University, Nanjing, China.
FAU - Gu, Yuxuan
AU  - Gu Y
AD  - Center for Health Policy Studies, School of Public Health, Zhejiang University 
      School of Medicine, Hangzhou, China.
FAU - Zhao, Zixuan
AU  - Zhao Z
AD  - Center for Health Policy Studies, School of Public Health, Zhejiang University 
      School of Medicine, Hangzhou, China.
FAU - Yang, Wei
AU  - Yang W
AD  - Shanghai Su-Value Health Scientific Ltd., Shanghai, China.
FAU - Dong, Hengjin
AU  - Dong H
AD  - Center for Health Policy Studies, School of Public Health, Zhejiang University 
      School of Medicine, Hangzhou, China.
AD  - The Fourth Affiliated Hospital Zhejiang University School of Medicine, Yiwu, 
      China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Ann Transl Med
JT  - Annals of translational medicine
JID - 101617978
PMC - PMC8105807
OTO - NOTNLM
OT  - Imrecoxib
OT  - celecoxib
OT  - cost-utility
OT  - osteoarthritis (OA)
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/atm-21-290). The authors have no 
      conflicts of interest to declare.
EDAT- 2021/05/15 06:00
MHDA- 2021/05/15 06:01
PMCR- 2021/04/01
CRDT- 2021/05/14 07:03
PHST- 2021/05/14 07:03 [entrez]
PHST- 2021/05/15 06:00 [pubmed]
PHST- 2021/05/15 06:01 [medline]
PHST- 2021/04/01 00:00 [pmc-release]
AID - atm-09-07-575 [pii]
AID - 10.21037/atm-21-290 [doi]
PST - ppublish
SO  - Ann Transl Med. 2021 Apr;9(7):575. doi: 10.21037/atm-21-290.